| Literature DB >> 31667145 |
Hossein Shooli1, Habibollah Dadgar2, Yì-Xiáng J Wáng3, Manochehr Seyedi Vafaee4,5,6, Saman Rassaei Kashuk1, Reza Nemati7, Esmail Jafari1, Iraj Nabipour8, Ali Gholamrezanezhad9, Majid Assadi1, Mykol Larvie10,11.
Abstract
PET imaging using novel radiotracers show promises for tumor grading and molecular characterization through visualizing molecular and functional properties of the tumors. Application of PET tracers in brain neoplasm depends on both type of the neoplasm and the research or clinical significance required to be addressed. In clinical neuro-oncology, 18F-FDG is used mainly to differentiate tumor recurrence from radiation-induced necrosis, and novel PET agents show attractive imaging properties. Novel PET tracers can offer biologic information not visible via contrast-enhanced MRI or 18F-FDG PET. This review aims to provide an update on the complementary role of PET imaging in neuro-oncology both in research and clinical settings along with presenting interesting cases in this context. 2019 Quantitative Imaging in Medicine and Surgery. All rights reserved.Entities:
Keywords: 68Ga-DOTA-peptide; 68Ga-labeled PSMA; Positron emission tomography (PET); brain tumors; magnetic resonance imaging (MRI); molecular imaging; precision medicine
Year: 2019 PMID： 31667145 PMCID： PMC6785513 DOI： 10.21037/qims.2019.08.16
Source DB: PubMed Journal: Quant Imaging Med Surg ISSN： 2223-4306